NKGen Biotech Receives Notifications From Nasdaq Related To Delayed Quarterly Report And Decision Of The Nasdaq Hearings Panel; The Company Does Not Intend To Appeal The Decision Letter At This Time And Intends To Deliver An Updated Plan Of Compliance To The Panel No Later Than January 7, 2025.
NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq")
Benzinga ·